Angiotensin Converting Enzyme‐2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver

Autor: Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Ross Laybutt, Sof Andrikopoulous, Ian E. Alexander, Mathew J. Watt, Peter W. Angus, Chandana B. Herath

Publikováno v: Hepatology Communications, Vol 6, Iss 5, Pp 1056-1072 (2022)

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is frequently associated with type 2 diabetes. However, there is no specific medical therapy to treat this condition. Angiotensin‐converting enzyme 2 (AC

Externí odkaz: https://doaj.org/article/08064fce3b5743cb8a28721cf571fa86

Liver‐Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug‐Resistant Gene 2‐Knockout Mice

Autor: Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Sharon C. Cunningham, Alexandra Sharland, Ian E. Alexander, Peter W. Angus, Chandana B. Herath

Publikováno v: Hepatology Communications, Vol 3, Iss 12, Pp 1656-1673 (2019)

There is a large unmet need for effective therapies for cholestatic disorders, including primary sclerosing cholangitis (PSC), a disease that commonly results in liver failure. Angiotensin (Ang) II of the renin Ang system (RAS) is a potent profibroti

Externí odkaz: https://doaj.org/article/6d5408cffc4642cfa702001e7df903ec

Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products

Autor: Dinali H. Fernando, Josephine M. Forbes, Peter W. Angus, Chandana B. Herath

Publikováno v: International Journal of Molecular Sciences, Vol 20, Iss 20, p 5037 (2019)

Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and deaths in the world. Treatment is largely based on lifestyle modification, which is difficult

Externí odkaz: https://doaj.org/article/c04f06cf160d47dcb547bbb8a649bb08

Clinical outcomes of patients with two small hepatocellular carcinomas

Autor: Karl Vaz, Numan Kutaiba, Paul J Gow, Niranjan Arachchi, Anouk Dev, Ammar Majeed, Michael A Fink, Sarah Gardner, Marie Sinclair, Stuart K. Roberts, Kurvi Patwala, Amanda Nicoll, Sally Bell, John S Lubel, Ning Mao Kam, Adam G Testro, Anh Duy Pham, Gauri Mishra, Peter W Angus, Siddharth Sood, Zaid S. Ardalan, Ross Apostolov, William Kemp

Publikováno v: World Journal of Hepatology

Background Management of single small hepatocellular carcinoma (HCC) is straightforward with curative outcomes achieved by locoregional therapy or resection. Liver transplantation is often considered for multiple small or single large HCC. Management

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e026554d6d81783b469b2814dcdaab
https://doi.org/10.4254/wjh.v13.i10.1439

Epidemiology and Prognostic Significance of Rapid Response System Activation in Patients Undergoing Liver Transplantation

Autor: Andrew Huynh, Tessa O’Halloran, William Chung, Ashley Bloom, Paul J Gow, Marcus Robertson, Andrew Tsoi, Daryl A Jones, Elise Cannan, Peter W Angus, Andy K.H. Lim, Ben Johnstone

Publikováno v: Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 5680, p 5680 (2021)
Journal of Clinical Medicine; Volume 10; Issue 23; Pages: 5680

Patients undergoing liver transplantation have a high risk of perioperative clinical deterioration. The Rapid Response System is an intensive care unit-based approach for the early recognition and management of hospitalized patients identified as hig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6cc3da831f617ceae11c47070606145
http://europepmc.org/articles/PMC8658097